title: Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis.
abstract: BACKGROUND
  To evaluate the effect of a therapeutic regimen of 7 days versus 14 days on the clinical manifestations of Helicobacter pylori gastritis in children.
  
  
  METHODS
  Ninety children (age 2-19 years) who had abdominal pain and/or recurrent vomiting were determined to have H. pylori gastritis by endoscopy, histology, and a Giemsa stain positive for H. pylori. The patients were randomized to receive amoxicillin, metronidazole, and bismuth subcitrate for 7 days (group A; 45 children) or 14 days (group B; 45 children) and were observed clinically for 19 +/- 11.5 months. Resolution of all abdominal and gastrointestinal symptoms was considered a good response.
  
  
  RESULTS
  A good response was obtained in 36 (80%) children from group A, and in 37 (82%) from group B. A recurrence of symptoms occurred in four (11%) of the responders from group A, and in six (15.2%) from group B.
  
  
  CONCLUSIONS
  A 7-day course of bismuth-based triple therapy for H. pylori gastritis in children appears to be clinically as effective as a 14-day regimen. The feasibility of a shorter therapeutic regimen may enhance patient compliance and provide a better chance of clinical benefit.
authors.affiliation: Division of Pediatric Gastroenterology and Nutrition, Rambam Medical Center, Haifa, Israel.
authors.forename: H
authors.initials: H
authors.lastname: Shamaly
authors.forename: D
authors.initials: D
authors.lastname: Berkowitz
authors.forename: E
authors.initials: E
authors.lastname: Rosenthal
authors.forename: Y
authors.initials: Y
authors.lastname: Naveh
mesh_terms: D015746:Abdominal Pain; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D012008:Recurrence; D017211:Treatment Failure; D014839:Vomiting
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D008795:Metronidazole; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole